[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$feL1QIh4SefC1mcjzZb3hwbMq7wEDPKPvw1AzydRCBps":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":79,"rows":86},"Medical University of Graz",[4],460,false,95,23,9252365,10,370,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Pulmonary Hypertension",16,{"name":18,"count":19},"Type 1 Diabetes",12,{"name":21,"count":22},"Psoriasis",9,{"name":24,"count":22},"Type 2 Diabetes",{"name":26,"count":22},"Obesity",{"name":28,"count":29},"Vitamin D Deficiency",8,{"name":31,"count":29},"Liver Cirrhosis",{"name":33,"count":34},"Polymorphic Light Eruption",6,[36,41,46,50,55,60,65,70,74],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05737030","Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome","2024-07-23","L-ornithine L-aspartate",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05032092","Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and\u002For Tissue Biopsy in Patients With Locally Advanced and\u002For Metastatic Solid Cancer","2025-12","Biomarker Monitoring",{"nctId":47,"briefTitle":48,"date":44,"intervention":49},"NCT04259359","Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure","Insect Venom",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT04552080","The Effect of Systemic Antibiotics on Post-surgical Complications and Patient-centered Outcomes in Patients Undergoing Implant Surgery With Guided Bone Regeneration and Simultaneous Sinus Floor Elevation","2026-03","Amoxicillin",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT03819803","Fecal Microbiota Transplantation in aGvHD After ASCT","2026-03-01","Fecal microbiota transplantation",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05293158","Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study","2026-06","Hepatect CP 50 I.E.\u002Fml infusion solution",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT05526443","Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)","2027-03","all approved chemotherapeutic agents from second line",{"nctId":71,"briefTitle":72,"date":68,"intervention":73},"NCT03188796","The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients","Cholecalciferol",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT07261787","Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minutes Versus 5 Minutes","2028-07-01","Poractant alfa (Curosurf®) - 1-minute administration",[80,81,82,83,84,85],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[87,111,133,161,179,242,264,298,321,343,366,401,435,466,484,502,520,547,565,591,609,636,663,687,713,737,762,780,798,824,842,866,892,910,936,963,981,1005,1031,1049,1075,1099,1133,1156,1180,1203,1228,1253,1281,1308,1326,1351,1374,1398,1424,1448,1474,1492,1519,1537,1560,1578,1613,1638,1660,1685,1703,1726,1749,1775,1793,1816,1843,1866,1891,1909,1933,1957,1981,1999,2024,2049,2067,2091,2116,2134,2152,2179,2197,2215,2233,2257,2282,2304,2326,2350,2376,2399,2422,2447,2470,2494,2517,2543,2569,2595,2618],{"intervention":40,"totalTrials":88,"cells":89},1,{"EARLY_PHASE1":90,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":99,"NA":109},{"trials":91,"activeCount":92},[],0,{"trials":94,"activeCount":92},[],{"trials":96,"activeCount":92},[],{"trials":98,"activeCount":92},[],{"trials":100,"activeCount":88,"soonestReadout":39},[101],{"nctId":37,"briefTitle":38,"status":102,"phases":103,"primaryCompletion":39,"completion":44,"start":104,"enrollment":105,"conditions":106,"interventions":108},"ACTIVE_NOT_RECRUITING",[84],"2023-02-06",55,[107],"Cirrhosis",[40],{"trials":110,"activeCount":92},[],{"intervention":54,"totalTrials":88,"cells":112},{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":119,"PHASE4":121,"NA":131},{"trials":114,"activeCount":92},[],{"trials":116,"activeCount":92},[],{"trials":118,"activeCount":92},[],{"trials":120,"activeCount":92},[],{"trials":122,"activeCount":88,"soonestReadout":53},[123],{"nctId":51,"briefTitle":52,"status":124,"phases":125,"primaryCompletion":53,"completion":53,"start":126,"enrollment":127,"conditions":128,"interventions":130},"RECRUITING",[84],"2022-12-29",30,[129],"Patients Undergoing Oral Implant Therapy",[54],{"trials":132,"activeCount":92},[],{"intervention":78,"totalTrials":88,"cells":134},{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":141,"PHASE4":143,"NA":159},{"trials":136,"activeCount":92},[],{"trials":138,"activeCount":92},[],{"trials":140,"activeCount":92},[],{"trials":142,"activeCount":92},[],{"trials":144,"activeCount":88,"soonestReadout":77},[145],{"nctId":75,"briefTitle":76,"status":124,"phases":146,"primaryCompletion":77,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":157},[84],"2028-12-01","2026-02-20",76,[151,152,153,154,155,156],"Neonates and Preterm Infants","Infant Respiratory Distress Syndrome","Surfactant Deficiency Syndrome Neonatal","Surfactant","Cerebral Oxygenation","Cerebral Oxygen Saturation",[78,158],"Poractant alfa (Curosurf®) - 5-minute administration",{"trials":160,"activeCount":92},[],{"intervention":158,"totalTrials":88,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":171,"NA":177},{"trials":164,"activeCount":92},[],{"trials":166,"activeCount":92},[],{"trials":168,"activeCount":92},[],{"trials":170,"activeCount":92},[],{"trials":172,"activeCount":88,"soonestReadout":77},[173],{"nctId":75,"briefTitle":76,"status":124,"phases":174,"primaryCompletion":77,"completion":147,"start":148,"enrollment":149,"conditions":175,"interventions":176},[84],[151,152,153,154,155,156],[78,158],{"trials":178,"activeCount":92},[],{"intervention":73,"totalTrials":180,"cells":181},5,{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":209,"NA":240},{"trials":183,"activeCount":92},[],{"trials":185,"activeCount":92},[],{"trials":187,"activeCount":92},[],{"trials":189,"activeCount":88,"soonestReadout":68},[190,201],{"nctId":191,"briefTitle":192,"status":193,"phases":194,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},"NCT01292720","Vitamin D Supplementation in Chronic Stable Heart Failure","COMPLETED",[83],"2013-10","2011-04",29,[199,28],"Heart Failure",[73],{"nctId":71,"briefTitle":72,"status":124,"phases":202,"primaryCompletion":68,"completion":68,"start":203,"enrollment":204,"conditions":205,"interventions":208},[83],"2017-10-10",2400,[206,28,207],"Critical Illness","Covid19",[73],{"trials":210,"activeCount":92},[211,221,231],{"nctId":212,"briefTitle":213,"status":193,"phases":214,"primaryCompletion":215,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":220},"NCT01390480","Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes",[84],"2013-11","2014-02","2010-11",31,[18],[73],{"nctId":222,"briefTitle":223,"status":193,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":230},"NCT01248442","Immune and Metabolic Effects of Vitamin D Supplementation in Healthy Humans",[84],"2010-06","2009-11",60,[229],"Healthy Humans",[73],{"nctId":232,"briefTitle":233,"status":193,"phases":234,"primaryCompletion":235,"completion":235,"start":236,"enrollment":16,"conditions":237,"interventions":239},"NCT01538485","Vitamin D Supplementation and Regulatory FoxP3+ T Cells in the GUT",[84],"2012-08","2012-01",[238],"Immune Tolerance",[73],{"trials":241,"activeCount":92},[],{"intervention":59,"totalTrials":88,"cells":243},{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":260,"NA":262},{"trials":245,"activeCount":92},[],{"trials":247,"activeCount":92},[],{"trials":249,"activeCount":92},[],{"trials":251,"activeCount":88,"soonestReadout":58},[252],{"nctId":56,"briefTitle":57,"status":124,"phases":253,"primaryCompletion":58,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":259},[83],"2026-12-31","2017-03-01",15,[258],"Graft Versus Host Disease in GI Tract",[59],{"trials":261,"activeCount":92},[],{"trials":263,"activeCount":92},[],{"intervention":49,"totalTrials":265,"cells":266},2,{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":275,"NA":277},{"trials":268,"activeCount":92},[],{"trials":270,"activeCount":92},[],{"trials":272,"activeCount":92},[],{"trials":274,"activeCount":92},[],{"trials":276,"activeCount":92},[],{"trials":278,"activeCount":88,"soonestReadout":44},[279,291],{"nctId":280,"briefTitle":281,"status":193,"phases":282,"primaryCompletion":283,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":290},"NCT04269629","The Effect of Antihypertensive Drugs on Severity of Anaphylaxis and Side-effects During Venom Immunotherapy",[],"2018-01","2019-03","2014-08",1425,[288,289],"Hymenoptera Venom Allergy","Antihypertensive Treatment",[49],{"nctId":47,"briefTitle":48,"status":124,"phases":292,"primaryCompletion":44,"completion":53,"start":293,"enrollment":294,"conditions":295,"interventions":297},[],"2019-05-02",266,[296],"Bee Venom Allergy",[49],{"intervention":69,"totalTrials":88,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":308,"NA":310},{"trials":301,"activeCount":92},[],{"trials":303,"activeCount":92},[],{"trials":305,"activeCount":92},[],{"trials":307,"activeCount":92},[],{"trials":309,"activeCount":92},[],{"trials":311,"activeCount":88,"soonestReadout":68},[312],{"nctId":66,"briefTitle":67,"status":124,"phases":313,"primaryCompletion":68,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":320},[],"2027-09","2023-01-13",1500,[318,319],"Pancreatic Cancer","Advanced Pancreatic Carcinoma",[69],{"intervention":64,"totalTrials":88,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":333},{"trials":324,"activeCount":92},[],{"trials":326,"activeCount":92},[],{"trials":328,"activeCount":92},[],{"trials":330,"activeCount":92},[],{"trials":332,"activeCount":92},[],{"trials":334,"activeCount":88,"soonestReadout":63},[335],{"nctId":61,"briefTitle":62,"status":336,"phases":337,"primaryCompletion":63,"completion":63,"start":338,"enrollment":180,"conditions":339,"interventions":342},"NOT_YET_RECRUITING",[85],"2024-11",[340,341],"Hepatocellular Carcinoma","HBV",[64],{"intervention":45,"totalTrials":88,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":355},{"trials":346,"activeCount":92},[],{"trials":348,"activeCount":92},[],{"trials":350,"activeCount":92},[],{"trials":352,"activeCount":92},[],{"trials":354,"activeCount":92},[],{"trials":356,"activeCount":88,"soonestReadout":44},[357],{"nctId":42,"briefTitle":43,"status":102,"phases":358,"primaryCompletion":44,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":365},[85],"2027-12","2021-11-24",235,[363,364],"Locally Advanced Carcinoma","Metastatic Cancer",[45],{"intervention":367,"totalTrials":265,"cells":368},"Tirbanibulin",{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":399},{"trials":370,"activeCount":92},[],{"trials":372,"activeCount":92},[],{"trials":374,"activeCount":92},[],{"trials":376,"activeCount":92},[],{"trials":378,"activeCount":92},[379,389],{"nctId":380,"briefTitle":381,"status":193,"phases":382,"primaryCompletion":383,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":388},"NCT05900258","Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face",[84],"2023-11-13","2023-05-11",22,[387],"Actinic Keratosis",[367],{"nctId":390,"briefTitle":391,"status":392,"phases":393,"primaryCompletion":394,"completion":394,"start":395,"enrollment":92,"conditions":396,"interventions":398},"NCT06026358","Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands","WITHDRAWN",[84],"2024-12","2023-10",[397],"Actinic Keratoses",[367],{"trials":400,"activeCount":92},[],{"intervention":402,"totalTrials":265,"cells":403},"Insulin aspart",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":415,"PHASE3":417,"PHASE4":419,"NA":433},{"trials":405,"activeCount":92},[],{"trials":407,"activeCount":92},[408],{"nctId":409,"briefTitle":410,"status":193,"phases":411,"primaryCompletion":412,"completion":412,"start":196,"enrollment":19,"conditions":413,"interventions":414},"NCT01399346","Investigation of the Impact of Different Application Volumes of Insulin Aspart in Subjects With Type 1 Diabetes",[81],"2011-06",[18],[402,402],{"trials":416,"activeCount":92},[],{"trials":418,"activeCount":92},[],{"trials":420,"activeCount":92},[421],{"nctId":422,"briefTitle":423,"status":193,"phases":424,"primaryCompletion":425,"completion":426,"start":225,"enrollment":427,"conditions":428,"interventions":429},"NCT01293396","Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids",[84],"2011-02","2011-03",20,[24],[430,431,432],"Insulin Aspart","Insulin Aspart 30","Insulin Aspart 70",{"trials":434,"activeCount":92},[],{"intervention":436,"totalTrials":88,"cells":437},"Fentanyl",{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":446,"NA":464},{"trials":439,"activeCount":92},[],{"trials":441,"activeCount":92},[],{"trials":443,"activeCount":92},[],{"trials":445,"activeCount":92},[],{"trials":447,"activeCount":92},[448],{"nctId":449,"briefTitle":450,"status":193,"phases":451,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":460},"NCT04026074","Concepts for Analgosedation During Placement of Regional Anaesthesia Before Operations.",[84],"2019-10-16","2019-10-18","2019-07-26",50,[457,458,459],"Knee Arthropathy","Hip Arthritis","Fractures, Closed",[436,461,462,463],"Remifentanil","Clonidine","EMLA Cream",{"trials":465,"activeCount":92},[],{"intervention":461,"totalTrials":88,"cells":467},{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":474,"PHASE4":476,"NA":482},{"trials":469,"activeCount":92},[],{"trials":471,"activeCount":92},[],{"trials":473,"activeCount":92},[],{"trials":475,"activeCount":92},[],{"trials":477,"activeCount":92},[478],{"nctId":449,"briefTitle":450,"status":193,"phases":479,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":480,"interventions":481},[84],[457,458,459],[436,461,462,463],{"trials":483,"activeCount":92},[],{"intervention":462,"totalTrials":88,"cells":485},{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":492,"PHASE4":494,"NA":500},{"trials":487,"activeCount":92},[],{"trials":489,"activeCount":92},[],{"trials":491,"activeCount":92},[],{"trials":493,"activeCount":92},[],{"trials":495,"activeCount":92},[496],{"nctId":449,"briefTitle":450,"status":193,"phases":497,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":498,"interventions":499},[84],[457,458,459],[436,461,462,463],{"trials":501,"activeCount":92},[],{"intervention":463,"totalTrials":88,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":518},{"trials":505,"activeCount":92},[],{"trials":507,"activeCount":92},[],{"trials":509,"activeCount":92},[],{"trials":511,"activeCount":92},[],{"trials":513,"activeCount":92},[514],{"nctId":449,"briefTitle":450,"status":193,"phases":515,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":516,"interventions":517},[84],[457,458,459],[436,461,462,463],{"trials":519,"activeCount":92},[],{"intervention":521,"totalTrials":88,"cells":522},"Telmisartan 80 mg",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":531,"NA":545},{"trials":524,"activeCount":92},[],{"trials":526,"activeCount":92},[],{"trials":528,"activeCount":92},[],{"trials":530,"activeCount":92},[],{"trials":532,"activeCount":92},[533],{"nctId":534,"briefTitle":535,"status":193,"phases":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":543},"NCT00407862","Telmisartan and Losartan in Hypertensive IGT",[84],"2006-06","2005-01",24,[541,542],"Hypertension","Impaired Glucose Tolerance",[521,544],"Losartan 50 mg",{"trials":546,"activeCount":92},[],{"intervention":544,"totalTrials":88,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":563},{"trials":550,"activeCount":92},[],{"trials":552,"activeCount":92},[],{"trials":554,"activeCount":92},[],{"trials":556,"activeCount":92},[],{"trials":558,"activeCount":92},[559],{"nctId":534,"briefTitle":535,"status":193,"phases":560,"completion":537,"start":538,"enrollment":539,"conditions":561,"interventions":562},[84],[541,542],[521,544],{"trials":564,"activeCount":92},[],{"intervention":566,"totalTrials":88,"cells":567},"Vitamin D supplementation in hypogonadal men",{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":576,"NA":589},{"trials":569,"activeCount":92},[],{"trials":571,"activeCount":92},[],{"trials":573,"activeCount":92},[],{"trials":575,"activeCount":92},[],{"trials":577,"activeCount":92},[578],{"nctId":579,"briefTitle":580,"status":193,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":587},"NCT01748370","Vitamin D Treatment and Hypogonadism in Men",[84],"2017-11-12","2012-12-01",200,[586],"Hypogonadism",[566,588],"Vitamin D supplementation in eugonadal men",{"trials":590,"activeCount":92},[],{"intervention":588,"totalTrials":88,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":601,"NA":607},{"trials":594,"activeCount":92},[],{"trials":596,"activeCount":92},[],{"trials":598,"activeCount":92},[],{"trials":600,"activeCount":92},[],{"trials":602,"activeCount":92},[603],{"nctId":579,"briefTitle":580,"status":193,"phases":604,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":605,"interventions":606},[84],[586],[566,588],{"trials":608,"activeCount":92},[],{"intervention":610,"totalTrials":88,"cells":611},"Dinoprostone",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":634},{"trials":613,"activeCount":92},[],{"trials":615,"activeCount":92},[],{"trials":617,"activeCount":92},[],{"trials":619,"activeCount":92},[],{"trials":621,"activeCount":92},[622],{"nctId":623,"briefTitle":624,"status":625,"phases":626,"primaryCompletion":627,"completion":628,"start":215,"enrollment":629,"conditions":630,"interventions":633},"NCT01720394","Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert","UNKNOWN",[84],"2019-07","2019-12",253,[631,632],"Cervical Ripening","Induction of Labor",[610],{"trials":635,"activeCount":92},[],{"intervention":637,"totalTrials":88,"cells":638},"Tramadol",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":647,"NA":661},{"trials":640,"activeCount":92},[],{"trials":642,"activeCount":92},[],{"trials":644,"activeCount":92},[],{"trials":646,"activeCount":92},[],{"trials":648,"activeCount":92},[649],{"nctId":650,"briefTitle":651,"status":193,"phases":652,"primaryCompletion":653,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":660},"NCT05237492","The Influence of Tramadol on Platelet Function",[84],"2023-07-15","2022-01-26",33,[657,658,659],"Drug Toxicity","Platelet Dysfunction","Clotting Disorder",[637],{"trials":662,"activeCount":92},[],{"intervention":664,"totalTrials":88,"cells":665},"Apremilast",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":674,"NA":685},{"trials":667,"activeCount":92},[],{"trials":669,"activeCount":92},[],{"trials":671,"activeCount":92},[],{"trials":673,"activeCount":92},[],{"trials":675,"activeCount":92},[676],{"nctId":677,"briefTitle":678,"status":392,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":92,"conditions":682,"interventions":684},"NCT04102449","Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast",[84],"2022-02","2020-07-01",[683],"Psoriatic Arthritis",[664],{"trials":686,"activeCount":92},[],{"intervention":688,"totalTrials":88,"cells":689},"Vitamin D supplementation",{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":696,"PHASE4":698,"NA":711},{"trials":691,"activeCount":92},[],{"trials":693,"activeCount":92},[],{"trials":695,"activeCount":92},[],{"trials":697,"activeCount":92},[],{"trials":699,"activeCount":92},[700],{"nctId":701,"briefTitle":702,"status":193,"phases":703,"primaryCompletion":704,"completion":704,"start":705,"enrollment":706,"conditions":707,"interventions":710},"NCT01721915","Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism",[84],"2017-10-12","2012-10",330,[708,709,28],"Polycystic Ovary Syndrome","Healthy",[688],{"trials":712,"activeCount":92},[],{"intervention":714,"totalTrials":88,"cells":715},"Insulin Aspart, Insulin Glargine",{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":724,"NA":735},{"trials":717,"activeCount":92},[],{"trials":719,"activeCount":92},[],{"trials":721,"activeCount":92},[],{"trials":723,"activeCount":92},[],{"trials":725,"activeCount":92},[726],{"nctId":727,"briefTitle":728,"status":193,"phases":729,"primaryCompletion":730,"completion":730,"start":412,"enrollment":731,"conditions":732,"interventions":734},"NCT01407289","A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia",[84],"2012-04",74,[733],"Diabetes Mellitus, Type 2",[714],{"trials":736,"activeCount":92},[],{"intervention":738,"totalTrials":88,"cells":739},"Amoxilan",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":760},{"trials":741,"activeCount":92},[],{"trials":743,"activeCount":92},[],{"trials":745,"activeCount":92},[],{"trials":747,"activeCount":92},[],{"trials":749,"activeCount":92},[750],{"nctId":751,"briefTitle":752,"status":193,"phases":753,"primaryCompletion":754,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":759},"NCT05142449","Effect of Systemic Antibiotic Therapy on Postoperative Complications in Patients Undergoing Wisdom Teeth Removal Surgery.",[84],"2022-09-01","2019-03-25",59,[758],"Third Molar Extraction Surgery",[738],{"trials":761,"activeCount":92},[],{"intervention":431,"totalTrials":88,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":772,"NA":778},{"trials":765,"activeCount":92},[],{"trials":767,"activeCount":92},[],{"trials":769,"activeCount":92},[],{"trials":771,"activeCount":92},[],{"trials":773,"activeCount":92},[774],{"nctId":422,"briefTitle":423,"status":193,"phases":775,"primaryCompletion":425,"completion":426,"start":225,"enrollment":427,"conditions":776,"interventions":777},[84],[24],[430,431,432],{"trials":779,"activeCount":92},[],{"intervention":432,"totalTrials":88,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":796},{"trials":783,"activeCount":92},[],{"trials":785,"activeCount":92},[],{"trials":787,"activeCount":92},[],{"trials":789,"activeCount":92},[],{"trials":791,"activeCount":92},[792],{"nctId":422,"briefTitle":423,"status":193,"phases":793,"primaryCompletion":425,"completion":426,"start":225,"enrollment":427,"conditions":794,"interventions":795},[84],[24],[430,431,432],{"trials":797,"activeCount":92},[],{"intervention":799,"totalTrials":88,"cells":800},"fluvastatin",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":822},{"trials":802,"activeCount":92},[],{"trials":804,"activeCount":92},[],{"trials":806,"activeCount":92},[],{"trials":808,"activeCount":92},[],{"trials":810,"activeCount":92},[811],{"nctId":812,"briefTitle":813,"status":193,"phases":814,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":820},"NCT00814723","Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk",[84],"2007-09","2005-09",90,[819],"Hypercholesterolemia",[799,821],"Fluvastatin plus ezetimibe",{"trials":823,"activeCount":92},[],{"intervention":821,"totalTrials":88,"cells":825},{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":832,"PHASE4":834,"NA":840},{"trials":827,"activeCount":92},[],{"trials":829,"activeCount":92},[],{"trials":831,"activeCount":92},[],{"trials":833,"activeCount":92},[],{"trials":835,"activeCount":92},[836],{"nctId":812,"briefTitle":813,"status":193,"phases":837,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":838,"interventions":839},[84],[819],[799,821],{"trials":841,"activeCount":92},[],{"intervention":843,"totalTrials":88,"cells":844},"Metformin Hydrochloride",{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":851,"PHASE4":853,"NA":864},{"trials":846,"activeCount":92},[],{"trials":848,"activeCount":92},[],{"trials":850,"activeCount":92},[],{"trials":852,"activeCount":92},[],{"trials":854,"activeCount":92},[855],{"nctId":856,"briefTitle":857,"status":193,"phases":858,"primaryCompletion":859,"completion":859,"start":860,"enrollment":861,"conditions":862,"interventions":863},"NCT04593459","Probiotic Intervention in PCOS",[84],"2023-10-16","2020-11-03",112,[708],[843],{"trials":865,"activeCount":92},[],{"intervention":867,"totalTrials":88,"cells":868},"GLP-1",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":877,"NA":890},{"trials":870,"activeCount":92},[],{"trials":872,"activeCount":92},[],{"trials":874,"activeCount":92},[],{"trials":876,"activeCount":92},[],{"trials":878,"activeCount":92},[879],{"nctId":880,"briefTitle":881,"status":193,"phases":882,"primaryCompletion":883,"completion":884,"start":537,"enrollment":29,"conditions":885,"interventions":888},"NCT00859079","Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients",[84],"2006-12","2007-01",[886,887],"Diabetes Mellitus Type 2","Hyperglycemia",[867,889],"Human regular insulin intravenously",{"trials":891,"activeCount":92},[],{"intervention":889,"totalTrials":88,"cells":893},{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":900,"PHASE4":902,"NA":908},{"trials":895,"activeCount":92},[],{"trials":897,"activeCount":92},[],{"trials":899,"activeCount":92},[],{"trials":901,"activeCount":92},[],{"trials":903,"activeCount":92},[904],{"nctId":880,"briefTitle":881,"status":193,"phases":905,"primaryCompletion":883,"completion":884,"start":537,"enrollment":29,"conditions":906,"interventions":907},[84],[886,887],[867,889],{"trials":909,"activeCount":92},[],{"intervention":911,"totalTrials":88,"cells":912},"Linagliptin",{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":919,"PHASE4":921,"NA":934},{"trials":914,"activeCount":92},[],{"trials":916,"activeCount":92},[],{"trials":918,"activeCount":92},[],{"trials":920,"activeCount":92},[],{"trials":922,"activeCount":92},[923],{"nctId":924,"briefTitle":925,"status":193,"phases":926,"primaryCompletion":927,"completion":928,"start":929,"enrollment":930,"conditions":931,"interventions":933},"NCT02350478","Effects of Linagliptin on Endothelial Function",[84],"2017-01","2017-03","2013-07",49,[24,932],"Coronary Artery Disease",[911],{"trials":935,"activeCount":92},[],{"intervention":937,"totalTrials":88,"cells":938},"Aflibercept 40 MG\u002FML",{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":943,"PHASE3":945,"PHASE4":947,"NA":961},{"trials":940,"activeCount":92},[],{"trials":942,"activeCount":92},[],{"trials":944,"activeCount":92},[],{"trials":946,"activeCount":92},[],{"trials":948,"activeCount":92},[949],{"nctId":950,"briefTitle":951,"status":193,"phases":952,"primaryCompletion":953,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":959},"NCT05941715","Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration",[84],"2024-09-25","2025-02-26","2023-07-04",70,[958],"Neovascular Age-related Macular Degeneration",[937,960],"Faricimab 120 MG\u002FML",{"trials":962,"activeCount":92},[],{"intervention":960,"totalTrials":88,"cells":964},{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":971,"PHASE4":973,"NA":979},{"trials":966,"activeCount":92},[],{"trials":968,"activeCount":92},[],{"trials":970,"activeCount":92},[],{"trials":972,"activeCount":92},[],{"trials":974,"activeCount":92},[975],{"nctId":950,"briefTitle":951,"status":193,"phases":976,"primaryCompletion":953,"completion":954,"start":955,"enrollment":956,"conditions":977,"interventions":978},[84],[958],[937,960],{"trials":980,"activeCount":92},[],{"intervention":982,"totalTrials":88,"cells":983},"Infliximab",{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":990,"PHASE4":992,"NA":1003},{"trials":985,"activeCount":92},[],{"trials":987,"activeCount":92},[],{"trials":989,"activeCount":92},[],{"trials":991,"activeCount":92},[],{"trials":993,"activeCount":92},[994],{"nctId":995,"briefTitle":996,"status":193,"phases":997,"primaryCompletion":998,"completion":815,"start":816,"enrollment":22,"conditions":999,"interventions":1002},"NCT00636142","Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity",[84],"2007-06",[26,1000,1001],"Insulin Resistance","Metabolic Syndrome",[982],{"trials":1004,"activeCount":92},[],{"intervention":1006,"totalTrials":88,"cells":1007},"Eye",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1014,"PHASE4":1016,"NA":1029},{"trials":1009,"activeCount":92},[],{"trials":1011,"activeCount":92},[],{"trials":1013,"activeCount":92},[],{"trials":1015,"activeCount":92},[],{"trials":1017,"activeCount":92},[1018],{"nctId":1019,"briefTitle":1020,"status":193,"phases":1021,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1027},"NCT04880928","Comparison Mydriasis by Mydrane With Topical Drop Application",[84],"2021-09-23","2020-08-12",42,[1026],"Cataract",[1006,1028,1028],"eye drops",{"trials":1030,"activeCount":92},[],{"intervention":1028,"totalTrials":88,"cells":1032},{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1041,"NA":1047},{"trials":1034,"activeCount":92},[],{"trials":1036,"activeCount":92},[],{"trials":1038,"activeCount":92},[],{"trials":1040,"activeCount":92},[],{"trials":1042,"activeCount":92},[1043],{"nctId":1019,"briefTitle":1020,"status":193,"phases":1044,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1045,"interventions":1046},[84],[1026],[1006,1028,1028],{"trials":1048,"activeCount":92},[],{"intervention":1050,"totalTrials":88,"cells":1051},"bDMARD withdrawal",{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1058,"PHASE4":1060,"NA":1073},{"trials":1053,"activeCount":92},[],{"trials":1055,"activeCount":92},[],{"trials":1057,"activeCount":92},[],{"trials":1059,"activeCount":92},[],{"trials":1061,"activeCount":92},[1062],{"nctId":1063,"briefTitle":1064,"status":1065,"phases":1066,"primaryCompletion":1067,"completion":1067,"start":1068,"enrollment":1069,"conditions":1070,"interventions":1072},"NCT01602302","Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis","TERMINATED",[84],"2020-11-19","2012-06",40,[1071],"Rheumatoid Arthritis",[1050],{"trials":1074,"activeCount":92},[],{"intervention":1076,"totalTrials":88,"cells":1077},"Imiquimod 3.75% Cream",{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1084,"PHASE4":1086,"NA":1097},{"trials":1079,"activeCount":92},[],{"trials":1081,"activeCount":92},[],{"trials":1083,"activeCount":92},[],{"trials":1085,"activeCount":92},[],{"trials":1087,"activeCount":92},[1088],{"nctId":1089,"briefTitle":1090,"status":193,"phases":1091,"primaryCompletion":1092,"completion":1092,"start":1093,"enrollment":1094,"conditions":1095,"interventions":1096},"NCT04842422","Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream",[84],"2021-08-23","2021-04-16",48,[397],[1076],{"trials":1098,"activeCount":92},[],{"intervention":1100,"totalTrials":265,"cells":1101},"Imiquimod",{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1129,"NA":1131},{"trials":1103,"activeCount":92},[],{"trials":1105,"activeCount":92},[],{"trials":1107,"activeCount":92},[],{"trials":1109,"activeCount":92},[1110,1120],{"nctId":1111,"briefTitle":1112,"status":193,"phases":1113,"primaryCompletion":1114,"completion":1114,"start":1115,"enrollment":1116,"conditions":1117,"interventions":1119},"NCT01861535","Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia",[83],"2021-02","2013-06",110,[1118],"Vulvar Intraepithelial Neoplasia",[1100],{"nctId":1121,"briefTitle":1122,"status":625,"phases":1123,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":227,"conditions":1126,"interventions":1128},"NCT01088737","Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna",[82,83],"2021-12","2011-01",[1127],"Lentigo Maligna",[1100],{"trials":1130,"activeCount":92},[],{"trials":1132,"activeCount":92},[],{"intervention":1134,"totalTrials":88,"cells":1135},"vitamin D",{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1142,"PHASE4":1152,"NA":1154},{"trials":1137,"activeCount":92},[],{"trials":1139,"activeCount":92},[],{"trials":1141,"activeCount":92},[],{"trials":1143,"activeCount":92},[1144],{"nctId":1145,"briefTitle":1146,"status":1065,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":225,"enrollment":385,"conditions":1149,"interventions":1151},"NCT01183442","Vitamin D Supplementation in CAD and Postchallenge Hyperglycemia",[83],"2012-11",[932,1150,28],"Postprandial Hyperglycemia",[1134],{"trials":1153,"activeCount":92},[],{"trials":1155,"activeCount":92},[],{"intervention":1157,"totalTrials":88,"cells":1158},"Atorvastatin",{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1165,"PHASE4":1176,"NA":1178},{"trials":1160,"activeCount":92},[],{"trials":1162,"activeCount":92},[],{"trials":1164,"activeCount":92},[],{"trials":1166,"activeCount":92},[1167],{"nctId":1168,"briefTitle":1169,"status":193,"phases":1170,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":1069,"conditions":1173,"interventions":1175},"NCT00844402","Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis",[83],"2007-11","2006-01",[1174,819],"Primary Biliary Cirrhosis",[1157],{"trials":1177,"activeCount":92},[],{"trials":1179,"activeCount":92},[],{"intervention":1181,"totalTrials":88,"cells":1182},"Physostigmine",{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1189,"PHASE4":1199,"NA":1201},{"trials":1184,"activeCount":92},[],{"trials":1186,"activeCount":92},[],{"trials":1188,"activeCount":92},[],{"trials":1190,"activeCount":92},[1191],{"nctId":1192,"briefTitle":1193,"status":193,"phases":1194,"primaryCompletion":1195,"completion":1195,"start":412,"enrollment":427,"conditions":1196,"interventions":1198},"NCT01394445","Pilot Study of Physostigmine-Enhanced Opioid Analgesia",[83],"2011-12",[1197],"Postoperative Pain",[1181],{"trials":1200,"activeCount":92},[],{"trials":1202,"activeCount":92},[],{"intervention":1204,"totalTrials":88,"cells":1205},"Fentanyl Transdermal System",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1212,"PHASE4":1224,"NA":1226},{"trials":1207,"activeCount":92},[],{"trials":1209,"activeCount":92},[],{"trials":1211,"activeCount":92},[],{"trials":1213,"activeCount":92},[1214],{"nctId":1215,"briefTitle":1216,"status":193,"phases":1217,"primaryCompletion":1218,"completion":1218,"start":1219,"enrollment":1220,"conditions":1221,"interventions":1223},"NCT04026022","Traumatologic Acute Pain Management With Fentanyl Transdermal Therapeutic System (TTS)",[83],"2020-03-06","2019-06-30",145,[1222],"Hip Fractures (ICD-10 72.01-72.2)",[1204],{"trials":1225,"activeCount":92},[],{"trials":1227,"activeCount":92},[],{"intervention":1229,"totalTrials":88,"cells":1230},"8-methoxypsoralen",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1249,"NA":1251},{"trials":1232,"activeCount":92},[],{"trials":1234,"activeCount":92},[],{"trials":1236,"activeCount":92},[],{"trials":1238,"activeCount":92},[1239],{"nctId":1240,"briefTitle":1241,"status":193,"phases":1242,"primaryCompletion":1243,"completion":1243,"start":1244,"enrollment":1245,"conditions":1246,"interventions":1248},"NCT01686594","PUVA Maintenance Therapy in Mycosis Fungoides",[83],"2018-07-02","2013-02",28,[1247],"Patch\u002FPlaque Stage Mycosis Fungoides",[1229],{"trials":1250,"activeCount":92},[],{"trials":1252,"activeCount":92},[],{"intervention":1254,"totalTrials":88,"cells":1255},"Ertugliflozin 5 mg",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1277,"NA":1279},{"trials":1257,"activeCount":92},[],{"trials":1259,"activeCount":92},[],{"trials":1261,"activeCount":92},[],{"trials":1263,"activeCount":92},[1264],{"nctId":1265,"briefTitle":1266,"status":1065,"phases":1267,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":105,"conditions":1271,"interventions":1276},"NCT04600921","Ertugliflozin to Reduce Arrhythmic Burden in ICD\u002FCRT patientS (ERASe-Trial) - a Phase III Study",[83],"2023-06-23","2023-10-18","2021-06-24",[1272,1273,1274,1275],"Heart Failure With Reduced Ejection Fraction","Heart Failure With Mid Range Ejection Fraction","Implantable Cardioverter-Defibrillators","Cardiac Resynchronization Therapy",[1254],{"trials":1278,"activeCount":92},[],{"trials":1280,"activeCount":92},[],{"intervention":1282,"totalTrials":88,"cells":1283},"Ultrasound guided regional anesthesia",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1290,"PHASE4":1304,"NA":1306},{"trials":1285,"activeCount":92},[],{"trials":1287,"activeCount":92},[],{"trials":1289,"activeCount":92},[],{"trials":1291,"activeCount":92},[1292],{"nctId":1293,"briefTitle":1294,"status":193,"phases":1295,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":455,"conditions":1298,"interventions":1302},"NCT04697537","Ultrasound-guided Regional Anesthesia vs Local Infiltration Anesthesia With Dexmedetomidine and Ropivacaine",[83],"2021-04-09","2021-02-01",[1299,1300,1301],"Pain, Postoperative","Anesthesia, Local","Gonarthrosis",[1282,1303],"Local infiltration analgesia",{"trials":1305,"activeCount":92},[],{"trials":1307,"activeCount":92},[],{"intervention":1303,"totalTrials":88,"cells":1309},{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1322,"NA":1324},{"trials":1311,"activeCount":92},[],{"trials":1313,"activeCount":92},[],{"trials":1315,"activeCount":92},[],{"trials":1317,"activeCount":92},[1318],{"nctId":1293,"briefTitle":1294,"status":193,"phases":1319,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":455,"conditions":1320,"interventions":1321},[83],[1299,1300,1301],[1282,1303],{"trials":1323,"activeCount":92},[],{"trials":1325,"activeCount":92},[],{"intervention":1327,"totalTrials":88,"cells":1328},"S-Ketamine",{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1347,"NA":1349},{"trials":1330,"activeCount":92},[],{"trials":1332,"activeCount":92},[],{"trials":1334,"activeCount":92},[],{"trials":1336,"activeCount":92},[1337],{"nctId":1338,"briefTitle":1339,"status":193,"phases":1340,"primaryCompletion":1341,"completion":1342,"start":1343,"enrollment":227,"conditions":1344,"interventions":1346},"NCT01022840","The Preemptive Analgetic Potency of Low Dose S-Ketamine",[83],"2012-03","2012-09","2009-02",[1345],"Pain",[1327],{"trials":1348,"activeCount":92},[],{"trials":1350,"activeCount":92},[],{"intervention":1352,"totalTrials":88,"cells":1353},"Pregabalin",{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1360,"PHASE4":1370,"NA":1372},{"trials":1355,"activeCount":92},[],{"trials":1357,"activeCount":92},[],{"trials":1359,"activeCount":92},[],{"trials":1361,"activeCount":92},[1362],{"nctId":1363,"briefTitle":1364,"status":193,"phases":1365,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":427,"conditions":1368,"interventions":1369},"NCT00957177","Analgetic Effect of Preoperative Pregabalin in Patients Undergoing Nephrectomy",[83],"2010-12","2009-04",[1197],[1352],{"trials":1371,"activeCount":92},[],{"trials":1373,"activeCount":92},[],{"intervention":1375,"totalTrials":88,"cells":1376},"Spermidine",{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1383,"PHASE4":1394,"NA":1396},{"trials":1378,"activeCount":92},[],{"trials":1380,"activeCount":92},[],{"trials":1382,"activeCount":92},[],{"trials":1384,"activeCount":92},[1385],{"nctId":1386,"briefTitle":1387,"status":625,"phases":1388,"primaryCompletion":1389,"completion":1389,"start":1390,"enrollment":1391,"conditions":1392,"interventions":1393},"NCT04405388","Spermidine Anti-Hypertension Study",[83],"2024-11-15","2020-02-25",46,[541],[1375],{"trials":1395,"activeCount":92},[],{"trials":1397,"activeCount":92},[],{"intervention":1399,"totalTrials":88,"cells":1400},"Empagliflozin 10 mg",{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1407,"PHASE4":1420,"NA":1422},{"trials":1402,"activeCount":92},[],{"trials":1404,"activeCount":92},[],{"trials":1406,"activeCount":92},[],{"trials":1408,"activeCount":92},[1409],{"nctId":1410,"briefTitle":1411,"status":193,"phases":1412,"primaryCompletion":1413,"completion":1414,"start":1415,"enrollment":1416,"conditions":1417,"interventions":1419},"NCT03087773","Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction",[83],"2022-05-03","2022-05-17","2017-05-11",476,[1418],"Acute Myocardial Infarction",[1399],{"trials":1421,"activeCount":92},[],{"trials":1423,"activeCount":92},[],{"intervention":1425,"totalTrials":88,"cells":1426},"Hyperbaric oxygen",{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1431,"PHASE3":1433,"PHASE4":1444,"NA":1446},{"trials":1428,"activeCount":92},[],{"trials":1430,"activeCount":92},[],{"trials":1432,"activeCount":92},[],{"trials":1434,"activeCount":92},[1435],{"nctId":1436,"briefTitle":1437,"status":625,"phases":1438,"primaryCompletion":1124,"completion":1439,"start":628,"enrollment":1440,"conditions":1441,"interventions":1443},"NCT02042339","Hyperbaric Oxygenation in Diabetic Ulcer",[83],"2022-12",80,[1442],"Diabetes Mellitus",[1425],{"trials":1445,"activeCount":92},[],{"trials":1447,"activeCount":92},[],{"intervention":1449,"totalTrials":88,"cells":1450},"ferric carboxymaltose",{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1457,"PHASE4":1470,"NA":1472},{"trials":1452,"activeCount":92},[],{"trials":1454,"activeCount":92},[],{"trials":1456,"activeCount":92},[],{"trials":1458,"activeCount":92},[1459],{"nctId":1460,"briefTitle":1461,"status":193,"phases":1462,"primaryCompletion":1463,"completion":1463,"start":1464,"enrollment":1465,"conditions":1466,"interventions":1468},"NCT01787526","Intravenous High Dose Iron in Blood Donors",[83],"2016-08","2014-06",176,[1467],"Iron Deficiency",[1449,1469],"oral iron",{"trials":1471,"activeCount":92},[],{"trials":1473,"activeCount":92},[],{"intervention":1469,"totalTrials":88,"cells":1475},{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1488,"NA":1490},{"trials":1477,"activeCount":92},[],{"trials":1479,"activeCount":92},[],{"trials":1481,"activeCount":92},[],{"trials":1483,"activeCount":92},[1484],{"nctId":1460,"briefTitle":1461,"status":193,"phases":1485,"primaryCompletion":1463,"completion":1463,"start":1464,"enrollment":1465,"conditions":1486,"interventions":1487},[83],[1467],[1449,1469],{"trials":1489,"activeCount":92},[],{"trials":1491,"activeCount":92},[],{"intervention":1493,"totalTrials":88,"cells":1494},"High-dose",{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1501,"PHASE4":1515,"NA":1517},{"trials":1496,"activeCount":92},[],{"trials":1498,"activeCount":92},[],{"trials":1500,"activeCount":92},[],{"trials":1502,"activeCount":92},[1503],{"nctId":1504,"briefTitle":1505,"status":1065,"phases":1506,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":1510,"interventions":1513},"NCT03472833","High-dose Vitamin D3 in Pancreas Cancer",[83],"2021-04-20","2018-04-01",25,[1511,28,1512],"Pancreas Cancer","Quality of Life",[1493,1514],"Standard dose",{"trials":1516,"activeCount":92},[],{"trials":1518,"activeCount":92},[],{"intervention":1514,"totalTrials":88,"cells":1520},{"EARLY_PHASE1":1521,"PHASE1":1523,"PHASE2":1525,"PHASE3":1527,"PHASE4":1533,"NA":1535},{"trials":1522,"activeCount":92},[],{"trials":1524,"activeCount":92},[],{"trials":1526,"activeCount":92},[],{"trials":1528,"activeCount":92},[1529],{"nctId":1504,"briefTitle":1505,"status":1065,"phases":1530,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":1531,"interventions":1532},[83],[1511,28,1512],[1493,1514],{"trials":1534,"activeCount":92},[],{"trials":1536,"activeCount":92},[],{"intervention":1538,"totalTrials":88,"cells":1539},"Oral Vitamin D 3",{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1546,"PHASE4":1556,"NA":1558},{"trials":1541,"activeCount":92},[],{"trials":1543,"activeCount":92},[],{"trials":1545,"activeCount":92},[],{"trials":1547,"activeCount":92},[1548],{"nctId":1549,"briefTitle":1550,"status":1065,"phases":1551,"primaryCompletion":1552,"completion":1552,"start":730,"enrollment":29,"conditions":1553,"interventions":1554},"NCT01595893","Vitamin D Supplementation in Polymorphic Light Eruption",[83],"2015-05",[33],[1538,1555],"Miglyol 812 N",{"trials":1557,"activeCount":92},[],{"trials":1559,"activeCount":92},[],{"intervention":1555,"totalTrials":88,"cells":1561},{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1566,"PHASE3":1568,"PHASE4":1574,"NA":1576},{"trials":1563,"activeCount":92},[],{"trials":1565,"activeCount":92},[],{"trials":1567,"activeCount":92},[],{"trials":1569,"activeCount":92},[1570],{"nctId":1549,"briefTitle":1550,"status":1065,"phases":1571,"primaryCompletion":1552,"completion":1552,"start":730,"enrollment":29,"conditions":1572,"interventions":1573},[83],[33],[1538,1555],{"trials":1575,"activeCount":92},[],{"trials":1577,"activeCount":92},[],{"intervention":1579,"totalTrials":265,"cells":1580},"Liraglutide",{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1582,"activeCount":92},[],{"trials":1584,"activeCount":92},[],{"trials":1586,"activeCount":92},[1587,1598],{"nctId":1588,"briefTitle":1589,"status":193,"phases":1590,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":1594,"interventions":1596},"NCT02408705","Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects",[82],"2016-05","2015-01",14,[1595],"Type 1 Diabetes Mellitus",[1579,1597],"Mixed Meal Tolerance Test with paracetamol",{"nctId":1599,"briefTitle":1600,"status":193,"phases":1601,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":256,"conditions":1604,"interventions":1605},"NCT01782261","Incretin Effect on the Immunological Phenotype",[82],"2015-02","2012-02",[18],[1579,1606],"Saxagliptin",{"trials":1608,"activeCount":92},[],{"trials":1610,"activeCount":92},[],{"trials":1612,"activeCount":92},[],{"intervention":1614,"totalTrials":88,"cells":1615},"HBO",{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1617,"activeCount":92},[],{"trials":1619,"activeCount":92},[],{"trials":1621,"activeCount":92},[1622],{"nctId":1623,"briefTitle":1624,"status":1065,"phases":1625,"primaryCompletion":1626,"completion":1626,"start":1627,"enrollment":1628,"conditions":1629,"interventions":1631},"NCT03101982","Hyperbaric Oxygenation (HBO) in Traumatic Spinal Cord Injury. (EOS) - Pilot Study",[82],"2024-12-20","2017-04-18",11,[1630],"Traumatic Injury of the Spinal Cord",[1614],{"trials":1633,"activeCount":92},[],{"trials":1635,"activeCount":92},[],{"trials":1637,"activeCount":92},[],{"intervention":1639,"totalTrials":88,"cells":1640},"autologous stored platelets",{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1654,"PHASE4":1656,"NA":1658},{"trials":1642,"activeCount":92},[],{"trials":1644,"activeCount":92},[],{"trials":1646,"activeCount":92},[1647],{"nctId":1648,"briefTitle":1649,"status":193,"phases":1650,"primaryCompletion":425,"completion":426,"start":217,"enrollment":34,"conditions":1651,"interventions":1653},"NCT01248351","Reversibility of Dual Antiplatelet Therapy by Platelets",[82],[1652],"Bleeding",[1639],{"trials":1655,"activeCount":92},[],{"trials":1657,"activeCount":92},[],{"trials":1659,"activeCount":92},[],{"intervention":1661,"totalTrials":88,"cells":1662},"ambrisentan",{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1664,"activeCount":92},[],{"trials":1666,"activeCount":92},[],{"trials":1668,"activeCount":92},[1669],{"nctId":1670,"briefTitle":1671,"status":392,"phases":1672,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":92,"conditions":1676,"interventions":1678},"NCT01733095","Ambrisentan for Treatment of Portopulmonary Hypertension",[81,82],"2016-04","2016-06","2012-07",[1677],"Portopulmonary Hypertension",[1661],{"trials":1680,"activeCount":92},[],{"trials":1682,"activeCount":92},[],{"trials":1684,"activeCount":92},[],{"intervention":1597,"totalTrials":88,"cells":1686},{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1691,"PHASE3":1697,"PHASE4":1699,"NA":1701},{"trials":1688,"activeCount":92},[],{"trials":1690,"activeCount":92},[],{"trials":1692,"activeCount":92},[1693],{"nctId":1588,"briefTitle":1589,"status":193,"phases":1694,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":1695,"interventions":1696},[82],[1595],[1579,1597],{"trials":1698,"activeCount":92},[],{"trials":1700,"activeCount":92},[],{"trials":1702,"activeCount":92},[],{"intervention":1704,"totalTrials":88,"cells":1705},"Insulin human",{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1720,"PHASE4":1722,"NA":1724},{"trials":1707,"activeCount":92},[],{"trials":1709,"activeCount":92},[],{"trials":1711,"activeCount":92},[1712],{"nctId":1713,"briefTitle":1714,"status":193,"phases":1715,"primaryCompletion":1716,"completion":1716,"start":1717,"enrollment":427,"conditions":1718,"interventions":1719},"NCT02028078","Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemia",[82],"2016-03","2014-01",[1595],[1704],{"trials":1721,"activeCount":92},[],{"trials":1723,"activeCount":92},[],{"trials":1725,"activeCount":92},[],{"intervention":1727,"totalTrials":88,"cells":1728},"Sodium-selenite",{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1743,"PHASE4":1745,"NA":1747},{"trials":1730,"activeCount":92},[],{"trials":1732,"activeCount":92},[],{"trials":1734,"activeCount":92},[1735],{"nctId":1736,"briefTitle":1737,"status":392,"phases":1738,"primaryCompletion":1739,"completion":627,"start":927,"enrollment":92,"conditions":1740,"interventions":1742},"NCT01390506","Selenium to Improve Neurological Outcome After Cardiac Arrest",[82],"2018-07",[1741],"Cardiac Arrest",[1727],{"trials":1744,"activeCount":92},[],{"trials":1746,"activeCount":92},[],{"trials":1748,"activeCount":92},[],{"intervention":1750,"totalTrials":88,"cells":1751},"Verapamil SR 120 mg",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1769,"PHASE4":1771,"NA":1773},{"trials":1753,"activeCount":92},[],{"trials":1755,"activeCount":92},[],{"trials":1757,"activeCount":92},[1758],{"nctId":1759,"briefTitle":1760,"status":193,"phases":1761,"primaryCompletion":1762,"completion":1763,"start":1764,"enrollment":1765,"conditions":1766,"interventions":1768},"NCT04545151","Verapamil SR in Adults With Type 1 Diabetes",[82],"2025-04-23","2026-04-17","2021-02-08",136,[1767],"Diabetes Mellitus, Type 1",[1750],{"trials":1770,"activeCount":92},[],{"trials":1772,"activeCount":92},[],{"trials":1774,"activeCount":92},[],{"intervention":1606,"totalTrials":88,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1787,"PHASE4":1789,"NA":1791},{"trials":1778,"activeCount":92},[],{"trials":1780,"activeCount":92},[],{"trials":1782,"activeCount":92},[1783],{"nctId":1599,"briefTitle":1600,"status":193,"phases":1784,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":256,"conditions":1785,"interventions":1786},[82],[18],[1579,1606],{"trials":1788,"activeCount":92},[],{"trials":1790,"activeCount":92},[],{"trials":1792,"activeCount":92},[],{"intervention":1794,"totalTrials":88,"cells":1795},"Benzbromarone",{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1800,"PHASE3":1810,"PHASE4":1812,"NA":1814},{"trials":1797,"activeCount":92},[],{"trials":1799,"activeCount":92},[],{"trials":1801,"activeCount":92},[1802],{"nctId":1803,"briefTitle":1804,"status":193,"phases":1805,"primaryCompletion":1463,"completion":1463,"start":1806,"enrollment":11,"conditions":1807,"interventions":1809},"NCT02790450","Acute Effects of Benzbromaron on the Pulmonary Circulation",[82],"2015-10",[1808],"Idiopathic Pulmonary Arterial Hypertension",[1794],{"trials":1811,"activeCount":92},[],{"trials":1813,"activeCount":92},[],{"trials":1815,"activeCount":92},[],{"intervention":1817,"totalTrials":88,"cells":1818},"Vorinostat Oral",{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1823,"PHASE3":1837,"PHASE4":1839,"NA":1841},{"trials":1820,"activeCount":92},[],{"trials":1822,"activeCount":92},[],{"trials":1824,"activeCount":92},[1825],{"nctId":1826,"briefTitle":1827,"status":1065,"phases":1828,"primaryCompletion":1829,"completion":1829,"start":1830,"enrollment":1831,"conditions":1832,"interventions":1836},"NCT03509207","Vorinostat (SAHA) in Uterine Sarcoma",[82],"2019-02-04","2017-12-14",3,[1833,1834,1835],"Leiomyosarcoma","Endometrial Stromal Tumors","Carcinosarcomas Uterine",[1817],{"trials":1838,"activeCount":92},[],{"trials":1840,"activeCount":92},[],{"trials":1842,"activeCount":92},[],{"intervention":1844,"totalTrials":88,"cells":1845},"Insulin LISPRO",{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1858,"PHASE3":1860,"PHASE4":1862,"NA":1864},{"trials":1847,"activeCount":92},[],{"trials":1849,"activeCount":92},[1850],{"nctId":1851,"briefTitle":1852,"status":193,"phases":1853,"primaryCompletion":1854,"completion":1717,"start":1855,"enrollment":427,"conditions":1856,"interventions":1857},"NCT01792323","Absorption of Insulin Following Subcutaneous Bolus Administration With Different Bolus Durations",[81],"2011-11","2011-08",[18],[1844],{"trials":1859,"activeCount":92},[],{"trials":1861,"activeCount":92},[],{"trials":1863,"activeCount":92},[],{"trials":1865,"activeCount":92},[],{"intervention":1867,"totalTrials":88,"cells":1868},"Levemir",{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1883,"PHASE3":1885,"PHASE4":1887,"NA":1889},{"trials":1870,"activeCount":92},[],{"trials":1872,"activeCount":92},[1873],{"nctId":1874,"briefTitle":1875,"status":193,"phases":1876,"primaryCompletion":1877,"completion":1877,"start":1878,"enrollment":127,"conditions":1879,"interventions":1881},"NCT00810589","A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial",[81],"2008-12","2008-11",[1880],"Diabetes, Type I",[1867,1882],"Humalog NPL Insulin",{"trials":1884,"activeCount":92},[],{"trials":1886,"activeCount":92},[],{"trials":1888,"activeCount":92},[],{"trials":1890,"activeCount":92},[],{"intervention":1882,"totalTrials":88,"cells":1892},{"EARLY_PHASE1":1893,"PHASE1":1895,"PHASE2":1901,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1894,"activeCount":92},[],{"trials":1896,"activeCount":92},[1897],{"nctId":1874,"briefTitle":1875,"status":193,"phases":1898,"primaryCompletion":1877,"completion":1877,"start":1878,"enrollment":127,"conditions":1899,"interventions":1900},[81],[1880],[1867,1882],{"trials":1902,"activeCount":92},[],{"trials":1904,"activeCount":92},[],{"trials":1906,"activeCount":92},[],{"trials":1908,"activeCount":92},[],{"intervention":1910,"totalTrials":88,"cells":1911},"Macrogol",{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1913,"activeCount":92},[],{"trials":1915,"activeCount":92},[],{"trials":1917,"activeCount":92},[],{"trials":1919,"activeCount":92},[],{"trials":1921,"activeCount":92},[],{"trials":1923,"activeCount":92},[1924],{"nctId":1925,"briefTitle":1926,"status":193,"phases":1927,"primaryCompletion":1928,"completion":1928,"start":1929,"enrollment":455,"conditions":1930,"interventions":1932},"NCT03395548","Stability of the Microbiome in IBD and IBS",[85],"2020-05-01","2017-08-25",[1931],"Microbiota",[1910],{"intervention":1934,"totalTrials":88,"cells":1935},"Calcipotriol-containing cream",{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1937,"activeCount":92},[],{"trials":1939,"activeCount":92},[],{"trials":1941,"activeCount":92},[],{"trials":1943,"activeCount":92},[],{"trials":1945,"activeCount":92},[],{"trials":1947,"activeCount":92},[1948],{"nctId":1949,"briefTitle":1950,"status":193,"phases":1951,"primaryCompletion":1952,"completion":1952,"start":1953,"enrollment":1954,"conditions":1955,"interventions":1956},"NCT00871052","Calcipotriol and Polymorphic Light Eruption",[85],"2009-05","2009-03",13,[33],[1934],{"intervention":1958,"totalTrials":88,"cells":1959},"Sodium bicarbonate",{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1966,"PHASE4":1968,"NA":1970},{"trials":1961,"activeCount":92},[],{"trials":1963,"activeCount":92},[],{"trials":1965,"activeCount":92},[],{"trials":1967,"activeCount":92},[],{"trials":1969,"activeCount":92},[],{"trials":1971,"activeCount":92},[1972],{"nctId":1973,"briefTitle":1974,"status":193,"phases":1975,"primaryCompletion":1976,"completion":1464,"start":426,"enrollment":1977,"conditions":1978,"interventions":1979},"NCT01362556","Blood Gas Analysis and Buffering In Cardiac Arrest",[85],"2013-12",700,[1741],[1958,1980],"Sodium Chloride",{"intervention":1980,"totalTrials":88,"cells":1982},{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1989,"PHASE4":1991,"NA":1993},{"trials":1984,"activeCount":92},[],{"trials":1986,"activeCount":92},[],{"trials":1988,"activeCount":92},[],{"trials":1990,"activeCount":92},[],{"trials":1992,"activeCount":92},[],{"trials":1994,"activeCount":92},[1995],{"nctId":1973,"briefTitle":1974,"status":193,"phases":1996,"primaryCompletion":1976,"completion":1464,"start":426,"enrollment":1977,"conditions":1997,"interventions":1998},[85],[1741],[1958,1980],{"intervention":2000,"totalTrials":88,"cells":2001},"To test the frequency of BRAF and NRAS mutations among nevi",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2008,"PHASE4":2010,"NA":2012},{"trials":2003,"activeCount":92},[],{"trials":2005,"activeCount":92},[],{"trials":2007,"activeCount":92},[],{"trials":2009,"activeCount":92},[],{"trials":2011,"activeCount":92},[],{"trials":2013,"activeCount":92},[2014],{"nctId":2015,"briefTitle":2016,"status":193,"phases":2017,"primaryCompletion":1953,"completion":2018,"start":2019,"enrollment":2020,"conditions":2021,"interventions":2023},"NCT00422448","Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.",[85],"2010-04","2006-09",43,[2022],"Nevi",[2000],{"intervention":2025,"totalTrials":88,"cells":2026},"propofol",{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2033,"PHASE4":2035,"NA":2037},{"trials":2028,"activeCount":92},[],{"trials":2030,"activeCount":92},[],{"trials":2032,"activeCount":92},[],{"trials":2034,"activeCount":92},[],{"trials":2036,"activeCount":92},[],{"trials":2038,"activeCount":92},[2039],{"nctId":2040,"briefTitle":2041,"status":193,"phases":2042,"primaryCompletion":196,"completion":196,"start":2043,"enrollment":2044,"conditions":2045,"interventions":2047},"NCT02588118","Gender and PK-PD of Propofol and Cisatracurium",[],"2010-01",120,[2046],"Gender",[2025,2048],"Cisatracurium",{"intervention":2048,"totalTrials":88,"cells":2050},{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2052,"activeCount":92},[],{"trials":2054,"activeCount":92},[],{"trials":2056,"activeCount":92},[],{"trials":2058,"activeCount":92},[],{"trials":2060,"activeCount":92},[],{"trials":2062,"activeCount":92},[2063],{"nctId":2040,"briefTitle":2041,"status":193,"phases":2064,"primaryCompletion":196,"completion":196,"start":2043,"enrollment":2044,"conditions":2065,"interventions":2066},[],[2046],[2025,2048],{"intervention":2068,"totalTrials":88,"cells":2069},"Vaccination against SARS-CoV-2",{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2076,"PHASE4":2078,"NA":2080},{"trials":2071,"activeCount":92},[],{"trials":2073,"activeCount":92},[],{"trials":2075,"activeCount":92},[],{"trials":2077,"activeCount":92},[],{"trials":2079,"activeCount":92},[],{"trials":2081,"activeCount":92},[2082],{"nctId":2083,"briefTitle":2084,"status":193,"phases":2085,"primaryCompletion":2086,"completion":2086,"start":2086,"enrollment":2087,"conditions":2088,"interventions":2090},"NCT06162533","Severe Acute Respiratory Syndrome Coronavirus 2 Re-Infection Risk and Vaccine Efficacy in Austria",[],"2023-07-01",9090868,[2089],"COVID-19",[2068],{"intervention":2089,"totalTrials":88,"cells":2092},{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2099,"PHASE4":2101,"NA":2103},{"trials":2094,"activeCount":92},[],{"trials":2096,"activeCount":92},[],{"trials":2098,"activeCount":92},[],{"trials":2100,"activeCount":92},[],{"trials":2102,"activeCount":92},[],{"trials":2104,"activeCount":92},[2105],{"nctId":2106,"briefTitle":2107,"status":625,"phases":2108,"primaryCompletion":2109,"completion":44,"start":1297,"enrollment":2110,"conditions":2111,"interventions":2114},"NCT04709302","Effects of COVID-19 on Endothelium in HIV-Positive Patients in Sub-Saharan Africa",[],"2024-06",342,[207,2112,2113],"Hiv","ART",[2089,2115,2113],"HIV",{"intervention":2115,"totalTrials":88,"cells":2117},{"EARLY_PHASE1":2118,"PHASE1":2120,"PHASE2":2122,"PHASE3":2124,"PHASE4":2126,"NA":2128},{"trials":2119,"activeCount":92},[],{"trials":2121,"activeCount":92},[],{"trials":2123,"activeCount":92},[],{"trials":2125,"activeCount":92},[],{"trials":2127,"activeCount":92},[],{"trials":2129,"activeCount":92},[2130],{"nctId":2106,"briefTitle":2107,"status":625,"phases":2131,"primaryCompletion":2109,"completion":44,"start":1297,"enrollment":2110,"conditions":2132,"interventions":2133},[],[207,2112,2113],[2089,2115,2113],{"intervention":2113,"totalTrials":88,"cells":2135},{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2140,"PHASE3":2142,"PHASE4":2144,"NA":2146},{"trials":2137,"activeCount":92},[],{"trials":2139,"activeCount":92},[],{"trials":2141,"activeCount":92},[],{"trials":2143,"activeCount":92},[],{"trials":2145,"activeCount":92},[],{"trials":2147,"activeCount":92},[2148],{"nctId":2106,"briefTitle":2107,"status":625,"phases":2149,"primaryCompletion":2109,"completion":44,"start":1297,"enrollment":2110,"conditions":2150,"interventions":2151},[],[207,2112,2113],[2089,2115,2113],{"intervention":2153,"totalTrials":88,"cells":2154},"5% Zovirax® cream",{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2159,"PHASE3":2161,"PHASE4":2163,"NA":2165},{"trials":2156,"activeCount":92},[],{"trials":2158,"activeCount":92},[],{"trials":2160,"activeCount":92},[],{"trials":2162,"activeCount":92},[],{"trials":2164,"activeCount":92},[],{"trials":2166,"activeCount":92},[2167],{"nctId":2168,"briefTitle":2169,"status":193,"phases":2170,"primaryCompletion":2171,"completion":2171,"start":1717,"enrollment":2172,"conditions":2173,"interventions":2175},"NCT02711267","Bioequivalence of Topical Acyclovir in Healthy Volunteers",[85],"2015-08",36,[2174],"Dermatologic Disorders",[2153,2176,2177,2178,2153],"5% Aciclostad cream","5% Aciclovir cream 1A Pharma","5% Zovirax Cold Sore Cream",{"intervention":2176,"totalTrials":88,"cells":2180},{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2185,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2182,"activeCount":92},[],{"trials":2184,"activeCount":92},[],{"trials":2186,"activeCount":92},[],{"trials":2188,"activeCount":92},[],{"trials":2190,"activeCount":92},[],{"trials":2192,"activeCount":92},[2193],{"nctId":2168,"briefTitle":2169,"status":193,"phases":2194,"primaryCompletion":2171,"completion":2171,"start":1717,"enrollment":2172,"conditions":2195,"interventions":2196},[85],[2174],[2153,2176,2177,2178,2153],{"intervention":2177,"totalTrials":88,"cells":2198},{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2203,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2200,"activeCount":92},[],{"trials":2202,"activeCount":92},[],{"trials":2204,"activeCount":92},[],{"trials":2206,"activeCount":92},[],{"trials":2208,"activeCount":92},[],{"trials":2210,"activeCount":92},[2211],{"nctId":2168,"briefTitle":2169,"status":193,"phases":2212,"primaryCompletion":2171,"completion":2171,"start":1717,"enrollment":2172,"conditions":2213,"interventions":2214},[85],[2174],[2153,2176,2177,2178,2153],{"intervention":2178,"totalTrials":88,"cells":2216},{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2223,"PHASE4":2225,"NA":2227},{"trials":2218,"activeCount":92},[],{"trials":2220,"activeCount":92},[],{"trials":2222,"activeCount":92},[],{"trials":2224,"activeCount":92},[],{"trials":2226,"activeCount":92},[],{"trials":2228,"activeCount":92},[2229],{"nctId":2168,"briefTitle":2169,"status":193,"phases":2230,"primaryCompletion":2171,"completion":2171,"start":1717,"enrollment":2172,"conditions":2231,"interventions":2232},[85],[2174],[2153,2176,2177,2178,2153],{"intervention":2234,"totalTrials":88,"cells":2235},"Human albumin",{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2242,"PHASE4":2244,"NA":2246},{"trials":2237,"activeCount":92},[],{"trials":2239,"activeCount":92},[],{"trials":2241,"activeCount":92},[],{"trials":2243,"activeCount":92},[],{"trials":2245,"activeCount":92},[],{"trials":2247,"activeCount":92},[2248],{"nctId":2249,"briefTitle":2250,"status":193,"phases":2251,"primaryCompletion":2252,"completion":2252,"start":2253,"enrollment":1069,"conditions":2254,"interventions":2256},"NCT03214796","Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status",[],"2024-12-31","2017-01-03",[2255],"Decompensated Cirrhosis",[2234],{"intervention":2258,"totalTrials":88,"cells":2259},"Steroids",{"EARLY_PHASE1":2260,"PHASE1":2262,"PHASE2":2264,"PHASE3":2266,"PHASE4":2268,"NA":2270},{"trials":2261,"activeCount":92},[],{"trials":2263,"activeCount":92},[],{"trials":2265,"activeCount":92},[],{"trials":2267,"activeCount":92},[],{"trials":2269,"activeCount":92},[],{"trials":2271,"activeCount":92},[2272],{"nctId":2273,"briefTitle":2274,"status":193,"phases":2275,"primaryCompletion":2276,"completion":2276,"start":2277,"enrollment":2278,"conditions":2279,"interventions":2281},"NCT03460847","Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa",[],"2021-03-01","2018-03-01",114,[2280],"Colitis, Ulcerative",[2258],{"intervention":2283,"totalTrials":88,"cells":2284},"Insulin dosing",{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2289,"PHASE3":2291,"PHASE4":2293,"NA":2295},{"trials":2286,"activeCount":92},[],{"trials":2288,"activeCount":92},[],{"trials":2290,"activeCount":92},[],{"trials":2292,"activeCount":92},[],{"trials":2294,"activeCount":92},[],{"trials":2296,"activeCount":92},[2297],{"nctId":2298,"briefTitle":2299,"status":193,"phases":2300,"primaryCompletion":1592,"completion":1592,"start":1717,"enrollment":29,"conditions":2301,"interventions":2303},"NCT02155023","Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors",[85],[2302],"Diabetes",[2283],{"intervention":2305,"totalTrials":88,"cells":2306},"keyhole-limpet hemocyanin",{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2308,"activeCount":92},[],{"trials":2310,"activeCount":92},[],{"trials":2312,"activeCount":92},[],{"trials":2314,"activeCount":92},[],{"trials":2316,"activeCount":92},[],{"trials":2318,"activeCount":92},[2319],{"nctId":2320,"briefTitle":2321,"status":193,"phases":2322,"primaryCompletion":705,"completion":705,"start":236,"enrollment":1593,"conditions":2323,"interventions":2325},"NCT01509391","Keyhole Limpet Hemocyanin in Chronic Hepatitis C",[85],[2324,31],"Chronic Hepatitis C",[2305],{"intervention":2327,"totalTrials":88,"cells":2328},"dosing of insulin",{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2335,"PHASE4":2337,"NA":2339},{"trials":2330,"activeCount":92},[],{"trials":2332,"activeCount":92},[],{"trials":2334,"activeCount":92},[],{"trials":2336,"activeCount":92},[],{"trials":2338,"activeCount":92},[],{"trials":2340,"activeCount":92},[2341],{"nctId":2342,"briefTitle":2343,"status":193,"phases":2344,"primaryCompletion":538,"completion":2345,"start":2346,"enrollment":1069,"conditions":2347,"interventions":2349},"NCT00733148","Correlation Between the Interstitial and Arterial Glucose in Post Surgery Patients",[],"2005-04","2004-07",[2348],"Intensive Care",[2327],{"intervention":2351,"totalTrials":88,"cells":2352},"Posaconazole",{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2359,"PHASE4":2361,"NA":2363},{"trials":2354,"activeCount":92},[],{"trials":2356,"activeCount":92},[],{"trials":2358,"activeCount":92},[],{"trials":2360,"activeCount":92},[],{"trials":2362,"activeCount":92},[],{"trials":2364,"activeCount":92},[2365],{"nctId":2366,"briefTitle":2367,"status":193,"phases":2368,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":2371,"conditions":2372,"interventions":2375},"NCT05065658","Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients",[],"2023-08-23","2020-03-01",249,[2373,2374],"COVID-19 Respiratory Infection","Aspergillosis",[2351],{"intervention":2377,"totalTrials":88,"cells":2378},"Nucleosome positioning",{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2383,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2380,"activeCount":92},[],{"trials":2382,"activeCount":92},[],{"trials":2384,"activeCount":92},[],{"trials":2386,"activeCount":92},[],{"trials":2388,"activeCount":92},[],{"trials":2390,"activeCount":92},[2391],{"nctId":2392,"briefTitle":2393,"status":625,"phases":2394,"primaryCompletion":395,"completion":395,"start":2395,"enrollment":756,"conditions":2396,"interventions":2398},"NCT03992521","Breast Cancer Liquid Biopsy Stratification",[],"2018-10-01",[2397],"Breast Cancer",[2377],{"intervention":2400,"totalTrials":88,"cells":2401},"insulin delivery",{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2408,"PHASE4":2410,"NA":2412},{"trials":2403,"activeCount":92},[],{"trials":2405,"activeCount":92},[],{"trials":2407,"activeCount":92},[],{"trials":2409,"activeCount":92},[],{"trials":2411,"activeCount":92},[],{"trials":2413,"activeCount":92},[2414],{"nctId":2415,"briefTitle":2416,"status":193,"phases":2417,"primaryCompletion":2418,"completion":2419,"start":1244,"enrollment":11,"conditions":2420,"interventions":2421},"NCT02359617","Continuous Glucose Sensing at the Site of Subcutaneous Insulin Administration",[85],"2014-10","2015-03",[18],[2400],{"intervention":2423,"totalTrials":88,"cells":2424},"Golimumab",{"EARLY_PHASE1":2425,"PHASE1":2427,"PHASE2":2429,"PHASE3":2431,"PHASE4":2433,"NA":2435},{"trials":2426,"activeCount":92},[],{"trials":2428,"activeCount":92},[],{"trials":2430,"activeCount":92},[],{"trials":2432,"activeCount":92},[],{"trials":2434,"activeCount":92},[],{"trials":2436,"activeCount":92},[2437],{"nctId":2438,"briefTitle":2439,"status":193,"phases":2440,"primaryCompletion":2441,"completion":2442,"start":2443,"enrollment":11,"conditions":2444,"interventions":2446},"NCT04200833","Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab",[],"2021-07-01","2021-08-01","2010-03-01",[2445],"JIA Associated Uveitis",[2423],{"intervention":2448,"totalTrials":88,"cells":2449},"Bosentan",{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2456,"PHASE4":2458,"NA":2460},{"trials":2451,"activeCount":92},[],{"trials":2453,"activeCount":92},[],{"trials":2455,"activeCount":92},[],{"trials":2457,"activeCount":92},[],{"trials":2459,"activeCount":92},[],{"trials":2461,"activeCount":92},[2462],{"nctId":2463,"briefTitle":2464,"status":193,"phases":2465,"primaryCompletion":225,"completion":225,"start":2466,"enrollment":11,"conditions":2467,"interventions":2469},"NCT00909337","Early Therapy of Pulmonary Arterial Hypertension",[85],"2008-01",[15,2468],"Systemic Sclerosis",[2448],{"intervention":2471,"totalTrials":88,"cells":2472},"Alefacept",{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2474,"activeCount":92},[],{"trials":2476,"activeCount":92},[],{"trials":2478,"activeCount":92},[],{"trials":2480,"activeCount":92},[],{"trials":2482,"activeCount":92},[],{"trials":2484,"activeCount":92},[2485],{"nctId":2486,"briefTitle":2487,"status":193,"phases":2488,"primaryCompletion":2489,"completion":2490,"start":2491,"enrollment":1593,"conditions":2492,"interventions":2493},"NCT00407342","Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.",[85],"2004-06","2004-09","2004-02",[21],[2471],{"intervention":2495,"totalTrials":88,"cells":2496},"Cranberry products",{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2503,"PHASE4":2505,"NA":2507},{"trials":2498,"activeCount":92},[],{"trials":2500,"activeCount":92},[],{"trials":2502,"activeCount":92},[],{"trials":2504,"activeCount":92},[],{"trials":2506,"activeCount":92},[],{"trials":2508,"activeCount":92},[2509],{"nctId":2510,"briefTitle":2511,"status":193,"phases":2512,"primaryCompletion":1124,"completion":2513,"start":1552,"enrollment":1765,"conditions":2514,"interventions":2516},"NCT02705495","Acupuncture for Prevention of Recurrent Urinary Tract Infections.",[85],"2022-06",[2515],"Recurrent Urinary Tract Infection",[2495],{"intervention":2518,"totalTrials":88,"cells":2519},"Factor XIII",{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2528,"NA":2530},{"trials":2521,"activeCount":92},[],{"trials":2523,"activeCount":92},[],{"trials":2525,"activeCount":92},[],{"trials":2527,"activeCount":92},[],{"trials":2529,"activeCount":92},[],{"trials":2531,"activeCount":92},[2532],{"nctId":2533,"briefTitle":2534,"status":193,"phases":2535,"primaryCompletion":2536,"completion":2537,"start":2538,"enrollment":2539,"conditions":2540,"interventions":2542},"NCT05933135","Factor XIII Activity in Gastrointestinal Bleedings",[],"2022-12-31","2023-12-31","2021-01-08",97,[2541],"Gastro Intestinal Bleeding",[2518],{"intervention":2544,"totalTrials":88,"cells":2545},"Cross-sectional genetics study",{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2550,"PHASE3":2552,"PHASE4":2554,"NA":2556},{"trials":2547,"activeCount":92},[],{"trials":2549,"activeCount":92},[],{"trials":2551,"activeCount":92},[],{"trials":2553,"activeCount":92},[],{"trials":2555,"activeCount":92},[],{"trials":2557,"activeCount":92},[2558],{"nctId":2559,"briefTitle":2560,"status":625,"phases":2561,"primaryCompletion":2562,"completion":2563,"start":2441,"enrollment":2564,"conditions":2565,"interventions":2568},"NCT04972708","Genetics of COVID-19 Risks & Resilience in Bipolar Disorder",[],"2024-09-01","2024-09-30",400,[2566,207,2567],"Bipolar Disorder","Stress",[2544],{"intervention":2570,"totalTrials":88,"cells":2571},"Immunotherapy",{"EARLY_PHASE1":2572,"PHASE1":2574,"PHASE2":2576,"PHASE3":2578,"PHASE4":2580,"NA":2582},{"trials":2573,"activeCount":92},[],{"trials":2575,"activeCount":92},[],{"trials":2577,"activeCount":92},[],{"trials":2579,"activeCount":92},[],{"trials":2581,"activeCount":92},[],{"trials":2583,"activeCount":92},[2584],{"nctId":2585,"briefTitle":2586,"status":625,"phases":2587,"primaryCompletion":2588,"completion":2589,"start":2590,"enrollment":2591,"conditions":2592,"interventions":2594},"NCT02159404","Nasal Mucus Proteome and Immunotherapy",[],"2025-01","2025-01-01","2015-04",88,[2593],"Allergic Rhinoconjunctivitis",[2570],{"intervention":2596,"totalTrials":88,"cells":2597},"PPI therapy",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2604,"PHASE4":2606,"NA":2608},{"trials":2599,"activeCount":92},[],{"trials":2601,"activeCount":92},[],{"trials":2603,"activeCount":92},[],{"trials":2605,"activeCount":92},[],{"trials":2607,"activeCount":92},[],{"trials":2609,"activeCount":92},[2610],{"nctId":2611,"briefTitle":2612,"status":193,"phases":2613,"primaryCompletion":2614,"completion":2614,"start":2418,"enrollment":19,"conditions":2615,"interventions":2617},"NCT02359604","The Gastrointestinal Microbiome of Infants With GERD and PPI Therapy: a Pilot Study",[85],"2017-02-07",[2616],"Gastroesophageal Reflux",[2596],{"intervention":2619,"totalTrials":88,"cells":2620},"Ivabradine 7.5mg orally",{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2622,"activeCount":92},[],{"trials":2624,"activeCount":92},[],{"trials":2626,"activeCount":92},[],{"trials":2628,"activeCount":92},[],{"trials":2630,"activeCount":92},[],{"trials":2632,"activeCount":92},[2633],{"nctId":2634,"briefTitle":2635,"status":193,"phases":2636,"primaryCompletion":2637,"completion":2638,"start":1602,"enrollment":861,"conditions":2639,"interventions":2641},"NCT02764970","Heart Rate Reducing Therapy in Cardiac CT Using Ivabradine and Bisoprolol",[],"2015-09","2016-01",[2640],"Bradycardia",[2619]]